vs

Side-by-side financial comparison of Cibus, Inc. (CBUS) and Insight Molecular Diagnostics Inc. (IMDX). Click either name above to swap in a different company.

Insight Molecular Diagnostics Inc. is the larger business by last-quarter revenue ($1.1M vs $1.1M, roughly 1.1× Cibus, Inc.). Insight Molecular Diagnostics Inc. runs the higher net margin — -2015.4% vs -2959.9%, a 944.5% gap on every dollar of revenue. On growth, Cibus, Inc. posted the faster year-over-year revenue change (-12.8% vs -23.4%). Insight Molecular Diagnostics Inc. produced more free cash flow last quarter ($-7.0M vs $-13.5M). Over the past eight quarters, Insight Molecular Diagnostics Inc.'s revenue compounded faster (154.4% CAGR vs 39.3%).

Cibus, Inc. is a leading agricultural biotechnology firm specializing in precision gene editing technologies to develop improved, sustainable crop traits. Its solutions include herbicide tolerance, disease and pest resistance, and enhanced yield characteristics for major row crops, serving global agricultural markets, seed producers, and farming communities to reduce environmental impact and boost operational efficiency.

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

CBUS vs IMDX — Head-to-Head

Bigger by revenue
IMDX
IMDX
1.1× larger
IMDX
$1.1M
$1.1M
CBUS
Growing faster (revenue YoY)
CBUS
CBUS
+10.6% gap
CBUS
-12.8%
-23.4%
IMDX
Higher net margin
IMDX
IMDX
944.5% more per $
IMDX
-2015.4%
-2959.9%
CBUS
More free cash flow
IMDX
IMDX
$6.5M more FCF
IMDX
$-7.0M
$-13.5M
CBUS
Faster 2-yr revenue CAGR
IMDX
IMDX
Annualised
IMDX
154.4%
39.3%
CBUS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CBUS
CBUS
IMDX
IMDX
Revenue
$1.1M
$1.1M
Net Profit
$-31.3M
$-23.0M
Gross Margin
42.5%
Operating Margin
-2135.7%
-2057.5%
Net Margin
-2959.9%
-2015.4%
Revenue YoY
-12.8%
-23.4%
Net Profit YoY
-35.4%
31.5%
EPS (diluted)
$-0.39
$-0.75

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBUS
CBUS
IMDX
IMDX
Q4 25
$1.1M
$1.1M
Q3 25
$615.0K
$260.0K
Q2 25
$933.0K
$518.0K
Q1 25
$1.0M
$2.1M
Q4 24
$1.2M
$1.5M
Q3 24
$1.7M
$115.0K
Q2 24
$838.0K
$104.0K
Q1 24
$545.0K
$176.0K
Net Profit
CBUS
CBUS
IMDX
IMDX
Q4 25
$-31.3M
$-23.0M
Q3 25
$-23.5M
$-10.9M
Q2 25
$-25.4M
$-9.7M
Q1 25
$-46.9M
$-6.7M
Q4 24
$-23.1M
$-33.5M
Q3 24
$-180.0M
$-13.5M
Q2 24
$-24.9M
$-4.5M
Q1 24
$-23.4M
$-9.1M
Gross Margin
CBUS
CBUS
IMDX
IMDX
Q4 25
42.5%
Q3 25
53.5%
Q2 25
67.6%
Q1 25
62.0%
Q4 24
40.0%
Q3 24
43.5%
Q2 24
48.1%
Q1 24
25.6%
Operating Margin
CBUS
CBUS
IMDX
IMDX
Q4 25
-2135.7%
-2057.5%
Q3 25
-2510.2%
-4249.2%
Q2 25
-1923.5%
-1900.0%
Q1 25
-4020.4%
-318.0%
Q4 24
-1487.1%
-2262.9%
Q3 24
-12023.8%
-11752.2%
Q2 24
-2563.5%
-4453.8%
Q1 24
-3385.9%
-5265.3%
Net Margin
CBUS
CBUS
IMDX
IMDX
Q4 25
-2959.9%
-2015.4%
Q3 25
-3827.8%
-4174.6%
Q2 25
-2719.4%
-1880.7%
Q1 25
-4534.4%
-312.0%
Q4 24
-1906.1%
-2255.1%
Q3 24
-10795.9%
-11733.0%
Q2 24
-2969.3%
-4355.8%
Q1 24
-4300.0%
-5186.9%
EPS (diluted)
CBUS
CBUS
IMDX
IMDX
Q4 25
$-0.39
$-0.75
Q3 25
$-0.44
$-0.34
Q2 25
$-0.61
$-0.30
Q1 25
$-1.34
$-0.26
Q4 24
$-0.94
$-2.19
Q3 24
$-7.63
$-0.98
Q2 24
$-1.14
$-0.36
Q1 24
$-1.12
$-1.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBUS
CBUS
IMDX
IMDX
Cash + ST InvestmentsLiquidity on hand
$9.9M
$11.6M
Total DebtLower is stronger
$528.0K
Stockholders' EquityBook value
$21.8M
$-31.5M
Total Assets
$305.0M
$25.8M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBUS
CBUS
IMDX
IMDX
Q4 25
$9.9M
$11.6M
Q3 25
$23.9M
$18.7M
Q2 25
$36.5M
$24.3M
Q1 25
$23.6M
$31.0M
Q4 24
$14.4M
$8.6M
Q3 24
$28.8M
$3.4M
Q2 24
$30.0M
$9.3M
Q1 24
$24.5M
$5.6M
Total Debt
CBUS
CBUS
IMDX
IMDX
Q4 25
$528.0K
Q3 25
Q2 25
Q1 25
Q4 24
$662.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CBUS
CBUS
IMDX
IMDX
Q4 25
$21.8M
$-31.5M
Q3 25
$50.4M
$-9.2M
Q2 25
$72.1M
$1.1M
Q1 25
$70.3M
$10.2M
Q4 24
$92.2M
$-12.3M
Q3 24
$108.1M
$9.7M
Q2 24
$270.5M
$22.7M
Q1 24
$278.2M
$11.6M
Total Assets
CBUS
CBUS
IMDX
IMDX
Q4 25
$305.0M
$25.8M
Q3 25
$330.2M
$43.9M
Q2 25
$346.2M
$50.5M
Q1 25
$335.0M
$60.4M
Q4 24
$350.1M
$35.1M
Q3 24
$367.9M
$70.2M
Q2 24
$553.4M
$74.7M
Q1 24
$533.0M
$71.0M
Debt / Equity
CBUS
CBUS
IMDX
IMDX
Q4 25
0.02×
Q3 25
Q2 25
Q1 25
Q4 24
0.01×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBUS
CBUS
IMDX
IMDX
Operating Cash FlowLast quarter
$-13.4M
$-5.5M
Free Cash FlowOCF − Capex
$-13.5M
$-7.0M
FCF MarginFCF / Revenue
-1277.8%
-616.7%
Capex IntensityCapex / Revenue
8.1%
129.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-51.2M
$-25.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBUS
CBUS
IMDX
IMDX
Q4 25
$-13.4M
$-5.5M
Q3 25
$-11.7M
$-4.5M
Q2 25
$-13.6M
$-6.3M
Q1 25
$-11.8M
$-5.9M
Q4 24
$-14.0M
$-5.4M
Q3 24
$-13.5M
$-5.5M
Q2 24
$-17.0M
$-6.0M
Q1 24
$-13.5M
$-3.8M
Free Cash Flow
CBUS
CBUS
IMDX
IMDX
Q4 25
$-13.5M
$-7.0M
Q3 25
$-11.8M
$-5.6M
Q2 25
$-13.7M
$-6.6M
Q1 25
$-12.1M
$-6.2M
Q4 24
$-14.1M
$-5.6M
Q3 24
$-13.9M
$-5.6M
Q2 24
$-17.2M
$-6.2M
Q1 24
$-13.7M
$-3.9M
FCF Margin
CBUS
CBUS
IMDX
IMDX
Q4 25
-1277.8%
-616.7%
Q3 25
-1926.5%
-2135.4%
Q2 25
-1468.1%
-1279.5%
Q1 25
-1172.0%
-288.4%
Q4 24
-1159.3%
-374.5%
Q3 24
-832.3%
-4884.3%
Q2 24
-2054.5%
-5931.7%
Q1 24
-2515.2%
-2189.8%
Capex Intensity
CBUS
CBUS
IMDX
IMDX
Q4 25
8.1%
129.9%
Q3 25
17.6%
403.8%
Q2 25
10.0%
67.4%
Q1 25
28.1%
14.4%
Q4 24
4.6%
14.4%
Q3 24
21.3%
75.7%
Q2 24
20.2%
183.7%
Q1 24
41.8%
13.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons